Business, energy, technology, markets and global industry news from Business News Today

respiratory drugs

PharmaDeviceNews respiratory drugs
Representative image: Chance Pharmaceuticals’ CXG87 asthma inhalation therapy filing in China highlights how improved dry powder inhaler design could reshape respiratory drug delivery and asthma control.
Pharma & Biotech

Can Chance Pharma’s asthma inhaler challenge Symbicort’s grip on China’s respiratory market?

Asthma drugs are familiar. Delivery remains the problem. CXG87 could test whether better inhaler engineering changes China’s asthma market.

Read More
Pharma & Biotech

What Glenmark Pharmaceuticals’ Ryaltris commercialization shift means for allergy drug competition

Glenmark Pharmaceuticals is taking direct control of Ryaltris in the U.S. Read what this shift means for allergy drug strategy and specialty growth.

Read More
Representative image of idiopathic pulmonary fibrosis treatment and specialty respiratory care, illustrating why Cipla’s U.S. nintedanib approval could reshape access, pricing, and competition in the pulmonary fibrosis drug market.
Pharma & Biotech

Cipla’s nintedanib approval opens a high-stakes test in the U.S. idiopathic pulmonary fibrosis market

Cipla’s nintedanib approval opens a new chapter in U.S. idiopathic pulmonary fibrosis care. Read what it changes for pricing, access, and competition.

Read More
Glenmark Pharmaceuticals secures U.S. FDA approval for fluticasone inhalation aerosol generic with 180-day exclusivity
Pharma & Biotech

How Glenmark Pharmaceuticals’ fluticasone inhaler approval could reshape the U.S. asthma inhaler market

Glenmark Pharmaceuticals wins FDA approval for generic fluticasone inhaler with 180-day exclusivity. Read what it means for the U.S. asthma drug market.

Read More